Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Cholangiocarcinoma 4Neoplasm Metastasis 2Carcinoma, Transitional Cell 2Acrocephalosyndactylia 2Stomach Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × pemigatinib × Clear all
NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04294277 2025-04-18

PEGASUS

European Association of Urology Research Foundation

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡